Kentaro Yamazaki

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Genetic Diversity

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

JCO precision oncology

Cancer chemotherapy and pharmacology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Naoko Iida, Mitsuho Imai, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, Hiromichi Ebi, Hiroya Taniguchi, Norio Nonomura, Yu Sunakawa, Manabu Shiozawa, Kentaro Yamazaki, Shogen Boku, Hideaki Bando, Yuichi Shiraishi, Maki Kobayashi, Hiroki Goto, Akihiro Sato, Satoshi Fujii, Takayuki Yoshino, Yoshiaki Nakamura
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Noboru Yamamoto, Takafumi Koyama, Toshio Shimizu, Akiko Todaka, Takeshi Kawakami, Damijan Erzen, Akiko Sarashina, Bin Li, Jianrui Hou, Kentaro Yamazaki
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 91 (6) (2023)
Yu Aoki, Yoshiaki Nakamura, Tadamichi Denda, Takashi Ohta, Taito Esaki, Manabu Shiozawa, Kensei Yamaguchi, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Naohiro Okano, Hiroya Taniguchi, Taroh Satoh, Eiji Oki, Tomohiro Nishina, Yoshito Komatsu, Nobuhisa Matsuhashi, Masahiro Goto, Hisateru Yasui, Koushiro Ohtsubo, Toshikazu Moriwaki, Naoki Takahashi, Yosuke Horita, Shogen Boku, Masashi Wakabayashi, Takashi Ikeno, Ryuta Mitani, Mihoko Yuasa, Takayuki Yoshino
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy. JCO precision oncology 7 (2023)
Kentaro Yamazaki, Satoshi Yuki, Eiji Oki, Fumikazu Sano, Misako Makishima, Kenichi Aoki, Tetsutaro Hamano, Kouji Yamamoto
Clinical outcomes of intensive versus less intensive first-line chemotherapy for metastatic colorectal cancer. Future oncology (London, England) (2023)
Kotoe Oshima, Kentaro Yamazaki
Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer. International journal of clinical oncology (2023)
Noboru Yamamoto, Takafumi Koyama, Toshio Shimizu, Akiko Todaka, Takeshi Kawakami, Damijan Erzen, Akiko Sarashina, Bin Li, Jianrui Hou, Kentaro Yamazaki
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology (2023)
Noboru Yamamoto, Takafumi Koyama, Toshio Shimizu, Akiko Todaka, Takeshi Kawakami, Damijan Erzen, Akiko Sarashina, Bin Li, Jianrui Hou, Kentaro Yamazaki
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology 91 (6) (2023)
Sae Ohwada, Akiko Todaka, Hiroshi Nakase, Hiromichi Shirasu, Takeshi Kawakami, Satoshi Hamauchi, Takahiro Tsushima, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study. Investigational new drugs 40 (5) (2022)
Kaori Hino, Tomohiro Nishina, Takeshi Kajiwara, Hideaki Bando, Maho Nakamura, Shigenori Kadowaki, Keiko Minashi, Satoshi Yuki, Takashi Ohta, Hiroki Hara, Takuro Mizukami, Toshikazu Moriwaki, Koushiro Ohtsubo, Masato Komoda, Seiichiro Mitani, Fumio Nagashima, Ken Kato, Takanobu Yamada, Hiroko Hasegawa, Kentaro Yamazaki, Takayuki Yoshino, Ichinosuke Hyodo
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer. JCO precision oncology 6 (2022)
Yoshiaki Nakamura, Wataru Okamoto, Tadamichi Denda, Tomohiro Nishina, Yoshito Komatsu, Satoshi Yuki, Hisateru Yasui, Taito Esaki, Yu Sunakawa, Makoto Ueno, Eiji Shinozaki, Nobuhisa Matsuhashi, Takashi Ohta, Ken Kato, Koushiro Ohtsubo, Hideaki Bando, Hiroki Hara, Taroh Satoh, Kentaro Yamazaki, Yoshiyuki Yamamoto, Naohiro Okano, Tetsuji Terazawa, Takeshi Kato, Eiji Oki, Akihito Tsuji, Yosuke Horita, Yasuo Hamamoto, Akihito Kawazoe, Hiromichi Nakajima, Shogo Nomura, Ryuta Mitani, Mihoko Yuasa, Kiwamu Akagi, Takayuki Yoshino
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO precision oncology 6 (2022)
Hideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, Manabu Shiozawa, Hisateru Yasui, Taito Esaki, Yoshinori Kagawa, Tadamichi Denda, Taroh Satoh, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Masahiro Goto, Satoshi Yuki, Tomohiro Nishina, Eiji Oki, Eiji Shinozaki, Nobuhisa Matsuhashi, Naoki Takahashi, Akihito Tsuji, Koushiro Ohtsubo, Masashi Wakabayashi, Takashi Ikeno, Masayuki Hata, Justin I Odegaard, Takayuki Yoshino
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. JCO precision oncology 6 (2022)
Masaaki Miyo, Takeshi Kato, Yoshiaki Nakamura, Hiroya Taniguchi, Yusuke Takahashi, Masayuki Ishii, Kenji Okita, Koji Ando, Hiroki Yukami, Saori Mishima, Kentaro Yamazaki, Masahito Kotaka, Jun Watanabe, Koji Oba, Alexey Aleshin, Paul R Billings, Matthew Rabinowitz, Daisuke Kotani, Eiji Oki, Ichiro Takemasa, Masaki Mori, Takayuki Yoshino
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer science (2021)
Hiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, Takeshi Kato, Satoshi Fujii, Hiromichi Ebi, Manabu Shiozawa, Satoshi Yuki, Toshiki Masuishi, Ken Kato, Naoki Izawa, Toshikazu Moriwaki, Eiji Oki, Yoshinori Kagawa, Tadamichi Denda, Tomohiro Nishina, Akihito Tsuji, Hiroki Hara, Taito Esaki, Tomohiro Nishida, Hiasto Kawakami, Yasutoshi Sakamoto, Izumi Miki, Wataru Okamoto, Kentaro Yamazaki, Takayuki Yoshino
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer science 112 (1) (2020)
Hiromichi Ebi, Hideaki Bando, Hiroya Taniguchi, Yu Sunakawa, Yoshinaga Okugawa, Yutaka Hatanaka, Waki Hosoda, Kensuke Kumamoto, Kaname Nakatani, Kentaro Yamazaki
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer science 111 (10) (2020)
Kentaro Yamazaki, Hiroya Taniguchi, Takayuki Yoshino, Kiwamu Akagi, Hideyuki Ishida, Hiromichi Ebi, Kaname Nakatani, Kei Muro, Yasushi Yatabe, Kensei Yamaguchi, Katsuya Tsuchihara
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. Cancer science 109 (6) (2018)
Takashi Kojima, Kentaro Yamazaki, Ken Kato, Kei Muro, Hiroki Hara, Keisho Chin, Thomas Goddemeier, Stefan Kuffel, Morihiro Watanabe, Toshihiko Doi
Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors. Cancer science 109 (10) (2018)